Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX) have been given an average rating of “Moderate Buy” by the eight brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $16.50.

Several analysts have recently issued reports on the stock. Mizuho set a $12.00 price target on shares of Immuneering in a research report on Wednesday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a report on Monday, December 29th. Leerink Partnrs raised shares of Immuneering to a “strong-buy” rating in a research report on Friday, October 31st. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Finally, Chardan Capital reiterated a “buy” rating and issued a $20.00 target price on shares of Immuneering in a report on Thursday, November 13th.

Immuneering Stock Down 1.9%

NASDAQ:IMRX opened at $4.14 on Wednesday. Immuneering has a 52 week low of $1.10 and a 52 week high of $10.08. The stock’s fifty day moving average is $6.49 and its two-hundred day moving average is $5.79. The stock has a market capitalization of $267.32 million, a price-to-earnings ratio of -2.33 and a beta of 0.48.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). On average, sell-side analysts expect that Immuneering will post -1.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Immuneering

A number of institutional investors and hedge funds have recently made changes to their positions in IMRX. Jane Street Group LLC purchased a new stake in shares of Immuneering during the first quarter worth approximately $32,000. China Universal Asset Management Co. Ltd. acquired a new position in Immuneering during the 3rd quarter worth approximately $35,000. Future Financial Wealth Managment LLC purchased a new stake in shares of Immuneering in the 3rd quarter valued at approximately $35,000. Kingsview Wealth Management LLC acquired a new stake in shares of Immuneering in the 2nd quarter valued at $47,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Immuneering during the 3rd quarter worth $70,000. 67.65% of the stock is owned by institutional investors and hedge funds.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.